Compare Abeona Therapeutics Inc (ABEO) vs HSBC Holdings plc (HSBC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs HSBC Holdings plc — how do they compare? Abeona Therapeutics Inc trades at $6.75 (market cap $373.32M), while HSBC Holdings plc trades at $95.95 (market cap $329.01B). The key difference: HSBC Holdings plc is far larger — about 881.3× Abeona Therapeutics Inc's market cap, and HSBC Holdings plc pays a 3.85% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | HSBC | |
|---|---|---|
Market Cap | $373.32M | $329.01B |
Sector | Health | Technology |
52-Week High | $7.23 | $98.74 |
52-Week Low | $4.17 | $61.30 |
Enterprise Value | $228.22M | — |
Dividend Yield | — | 3.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
HSBC trades at $98.74, up 2.03% with bullish technical indicators and strong earnings momentum. The stock shows consistent earnings beats with Q1 2026 EPS of $2.20 exceeding expectations. Recent developments include strategic reviews of non-core businesses and AI partnerships with Google Cloud. Valuation metrics include a P/E of 16.32 and P/B of 1.72, while maintaining a 30.81% net income margin.
HSBC presents a balanced investment case with solid fundamentals and strategic repositioning offset by regulatory risks and market volatility. The bank's focus on core markets and AI integration supports growth potential, though recent regulatory penalties and business exits warrant monitoring. Analyst consensus leans neutral with 52.38% hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →
